Loading...
XJPX
4563
Market cap176mUSD
Aug 08, Last price  
80.00JPY
1D
9.59%
1Q
19.40%
Jan 2017
-68.00%
IPO
-95.28%
Name

AnGes Inc

Chart & Performance

D1W1MN
P/E
P/S
40.62
EPS
Div Yield, %
Shrs. gr., 5y
17.58%
Rev. gr., 5y
14.50%
Revenues
643m
+320.30%
951,147,000585,695,000286,915,000243,391,000444,508,000491,310,000909,921,000430,154,000514,269,000365,182,000610,050,000326,759,00039,998,00064,147,00067,061,000152,985,000643,000,000
Net income
-28.13b
L+278.19%
-3,534,371,000-2,921,390,000-1,967,217,000-1,815,061,000-1,708,366,000-1,409,686,000-2,369,205,000-4,143,335,000-4,776,780,000-3,764,699,000-2,996,629,000-3,750,824,000-4,209,510,000-13,675,588,000-14,714,772,000-7,437,607,000-28,128,000,000
CFO
-6.61b
L-24.38%
-1,978,065,000-2,225,095,000-1,842,885,000-1,705,801,000-1,631,074,000-1,456,637,000-2,703,624,000-4,599,416,000-4,983,694,000-2,991,223,000-2,522,501,000-2,179,918,000-2,961,329,000-11,380,546,000-11,214,246,000-8,745,000,000-6,612,875,000

Profile

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.
IPO date
Sep 25, 2002
Employees
138
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
643,000
320.30%
152,985
128.13%
67,061
4.54%
Cost of revenue
9,753,000
8,817,944
21,087,205
Unusual Expense (Income)
NOPBT
(9,110,000)
(8,664,959)
(21,020,144)
NOPBT Margin
Operating Taxes
485,000
(33,807)
(2,222)
Tax Rate
NOPAT
(9,595,000)
(8,631,152)
(21,017,922)
Net income
(28,128,000)
278.19%
(7,437,607)
-49.45%
(14,714,772)
7.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,008,401
2,033,141
3,521,622
BB yield
-24.12%
-14.92%
-18.50%
Debt
Debt current
163,000
147,726
160,743
Long-term debt
379,000
577,624
2,150,681
Deferred revenue
64,317
Other long-term liabilities
91,000
64,430
3
Net debt
(1,705,000)
(3,790,619)
(9,645,251)
Cash flow
Cash from operating activities
(6,612,875)
(8,745,000)
(11,214,246)
CAPEX
(67,000)
(89,331)
(19,569)
Cash from investing activities
(130,801)
(356,653)
(97,141)
Cash from financing activities
4,202,127
2,036,465
3,572,543
FCF
(9,712,828)
(7,545,264)
(22,235,648)
Balance
Cash
1,707,000
4,160,424
11,035,102
Long term investments
540,000
355,545
921,573
Excess cash
2,214,850
4,508,320
11,953,322
Stockholders' equity
(9,259,594)
22,678,280
12,957,743
Invested Capital
11,778,193
22,021,952
19,543,777
ROIC
ROCE
EV
Common stock shares outstanding
235,326
189,277
156,053
Price
53.00
-26.39%
72.00
-40.98%
122.00
-68.23%
Market cap
12,472,288
-8.48%
13,627,922
-28.42%
19,038,451
-66.34%
EV
10,767,288
9,837,303
9,393,200
EBITDA
(5,738,359)
(5,555,902)
(18,118,320)
EV/EBITDA
Interest
20,217
Interest/NOPBT